Lupin Limited has announced the launch of Varenicline Tablets, 0.5 mg and 1 mg, after having received an approval from the United States Food and Drug Administration (USFDA).

Varenicline Tablets, 0.5 mg and 1 mg is the generic equivalent of Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. It is indicated for use as an aid to smoking cessation treatment.

Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US (IQVIA MAT November 2023).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the US by prescription. The company invested 7.9% of its revenue in research and development in FY23.